| __timestamp | Amneal Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 106352000 |
| Thursday, January 1, 2015 | 367054000 | 144969000 |
| Friday, January 1, 2016 | 420770000 | 162364000 |
| Sunday, January 1, 2017 | 507476000 | 188462000 |
| Monday, January 1, 2018 | 946588000 | 210850000 |
| Tuesday, January 1, 2019 | 1273376000 | 240515000 |
| Wednesday, January 1, 2020 | 1364130000 | 255497000 |
| Friday, January 1, 2021 | 1324696000 | 298182000 |
| Saturday, January 1, 2022 | 1427596000 | 349103000 |
| Sunday, January 1, 2023 | 1573042000 | 366887000 |
| Monday, January 1, 2024 | 389335000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Amneal Pharmaceuticals has seen a staggering 368% increase in its cost of revenue, peaking at approximately $1.57 billion in 2023. In contrast, Bio-Techne Corporation has maintained a more modest growth, with a 245% increase, reaching around $389 million in the same year.
The data highlights a significant disparity in cost management strategies between the two companies. While Amneal's costs have surged, Bio-Techne's more controlled growth suggests a strategic focus on efficiency. This insight is crucial for investors and industry analysts seeking to understand the financial dynamics and operational strategies within the biotech and pharmaceutical sectors.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Incyte Corporation vs Amneal Pharmaceuticals, Inc.
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Alkermes plc vs Amneal Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored